Differentiating agents in the treatment of human malignancies

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Current Status of U.S. Clinical Trials in Chronic Lymphocytic Leukemia.

Leukemia & lymphoma·2016

Phase II Trial of Fludarabine Phosphate in Multiple Myeloma Using a Loading Dose and Continuous Infusion Schedule.

Leukemia & lymphoma·2016

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.

Leukemia·2015

Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.

Blood cancer journal·2014

Glioblastoma and resistance to radiotherapy: role of cancer stem cells subpopulations, hypoxia and therapeutic strategies.

Cancer treatment reviews·2026

Vinorelbine and low-dose cyclophosphamide as maintenance therapy in the treatment of Ewing sarcoma rationale for the international INTER-EWING-1 trial for Ewing sarcoma patients.

Cancer treatment reviews·2026

Is Cytoreductive surgery for unresectable colorectal liver metastases able to improve patient outcome? Results of a pilot prospective study.

Cancer treatment reviews·2026

Chondrosarcoma: A comprehensive review of tumor biology, clinical behavior, and therapeutic advances.

Cancer treatment reviews·2026

Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception.

Cancer treatment reviews·2026

Understanding extrapulmonary neuroendocrine carcinomas: Survival, prognosis, and patient quality of life.

Cancer treatment reviews·2026

Inhibition of miR-301a-3p Expression Promotes Ferroptosis: A New Target for Ferroptosis Treatment in TNBC.

The breast journal·2026

Research progress on BTG2 in non‑tumor diseases (Review).

International journal of molecular medicine·2026

Advances in sirtuin research in lung diseases (Review).

International journal of molecular medicine·2026

Breaking the cycle of fibrosis: Ferroptosis as a therapeutic target (Review).

International journal of molecular medicine·2026

[Expression of Concern] Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells.

Oncology reports·2026

Do Generic EGFR-TKIs Perform as Well as Innovators? Real-World Evidence from Gefitinib-Treated EGFR-Mutated NSCLC in Indonesia.

Asian Pacific journal of cancer prevention : APJCP·2026

Related Experiment Videos

Differentiating agents in the treatment of human malignancies

Related Concept Videos

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Current Status of U.S. Clinical Trials in Chronic Lymphocytic Leukemia.

Phase II Trial of Fludarabine Phosphate in Multiple Myeloma Using a Loading Dose and Continuous Infusion Schedule.

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.

Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.

Glioblastoma and resistance to radiotherapy: role of cancer stem cells subpopulations, hypoxia and therapeutic strategies.

Vinorelbine and low-dose cyclophosphamide as maintenance therapy in the treatment of Ewing sarcoma rationale for the international INTER-EWING-1 trial for Ewing sarcoma patients.

Is Cytoreductive surgery for unresectable colorectal liver metastases able to improve patient outcome? Results of a pilot prospective study.

Chondrosarcoma: A comprehensive review of tumor biology, clinical behavior, and therapeutic advances.

Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception.

Understanding extrapulmonary neuroendocrine carcinomas: Survival, prognosis, and patient quality of life.

Inhibition of miR-301a-3p Expression Promotes Ferroptosis: A New Target for Ferroptosis Treatment in TNBC.

Research progress on BTG2 in non‑tumor diseases (Review).

Advances in sirtuin research in lung diseases (Review).

Breaking the cycle of fibrosis: Ferroptosis as a therapeutic target (Review).

[Expression of Concern] Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells.

Do Generic EGFR-TKIs Perform as Well as Innovators? Real-World Evidence from Gefitinib-Treated EGFR-Mutated NSCLC in Indonesia.

Related Experiment Videos

Differentiating agents in the treatment of human malignancies

Related Concept Videos

Related Articles